Skip to main content
Top
Published in: Globalization and Health 1/2014

Open Access 01-12-2014 | Research

Enhancing medicine price transparency through price information mechanisms

Authors: Michael Hinsch, Miloud Kaddar, Sarah Schmitt

Published in: Globalization and Health | Issue 1/2014

Login to get access

Abstract

Background

Medicine price information mechanisms provide an essential tool to countries that seek a better understanding of product availability, market prices and price compositions of individual medicines. To be effective and contribute to cost savings, these mechanisms need to consider prices in their particular contexts when comparing between countries. This article discusses in what ways medicine price information mechanisms can contribute to increased price transparency and how this may affect access to medicines for developing countries.

Methods

We used data collected during the course of a WHO project focusing on the development of a vaccine price and procurement information mechanism. The project collected information from six medicine price information mechanisms and interviewed data managers and technical experts on key aspects as well as observed market effects of these mechanisms.
The reviewed mechanisms were broken down into categories including objective and target audience, as well as the sources, types and volumes of data included. Information provided by the mechanisms was reviewed according to data available on medicine prices, product characteristics, and procurement modalities.

Results

We found indications of positive effects on access to medicines resulting from the utilization of the reviewed mechanisms. These include the uptake of higher quality medicines, more favorable results from contract negotiations, changes in national pricing policies, and the decrease of prices in certain segments for countries participating in or deriving data from the various mechanisms.

Conclusion

The reviewed mechanisms avoid the methodological challenges observed for medicine price comparisons that only use national price databases. They work with high quality data and display prices in the appropriate context of procurement modalities as well as the peculiarities of purchasing countries. Medicine price information mechanisms respond to the need for increased medicine price transparency and have the potential to contribute to improved access to medicines in developing countries.
Additional research is required to explore more specific aspects. These include the market effects of dedicated donor funds for certain medicines to explain the driving force of user demands, and the effects of increased price transparency on different groups of medicines in context of the maturity of their markets.
Literature
1.
go back to reference Kyle MK, Ridley DB: Would greater transparency and uniformity of health care prices benefit poor patients?. Health Aff. 2007, 26 (5): 1384-1391. 10.1377/hlthaff.26.5.1384.CrossRef Kyle MK, Ridley DB: Would greater transparency and uniformity of health care prices benefit poor patients?. Health Aff. 2007, 26 (5): 1384-1391. 10.1377/hlthaff.26.5.1384.CrossRef
3.
go back to reference World Health Organization: More Equitable Pricing for Essential Drugs: What do we Mean and What are the Issues?. Background Paper for the WHO-WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs: 8–11 April 2001. 2001, Geneva, Switzerland: Høsbjør World Health Organization: More Equitable Pricing for Essential Drugs: What do we Mean and What are the Issues?. Background Paper for the WHO-WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs: 8–11 April 2001. 2001, Geneva, Switzerland: Høsbjør
4.
go back to reference World Health Organization, Health Action International: Measuring Medicine Prices, Availability and Price Components. 2008, Geneva, Switzerland: World Health Organization, 2 World Health Organization, Health Action International: Measuring Medicine Prices, Availability and Price Components. 2008, Geneva, Switzerland: World Health Organization, 2
5.
go back to reference World Health Organization: World Health Statistics 2012. 2012, Geneva, Switzerland: World Health Organization World Health Organization: World Health Statistics 2012. 2012, Geneva, Switzerland: World Health Organization
6.
go back to reference World Health Organization: The World Medicines Situation 2011. Medicines Prices, Availability and Affordability. 2011, Geneva, Switzerland: World Health Organization World Health Organization: The World Medicines Situation 2011. Medicines Prices, Availability and Affordability. 2011, Geneva, Switzerland: World Health Organization
7.
go back to reference Management Sciences for Health, World Health Organization: International Drug Price Indicator Guide. 2010, Cambridge MA, USA: Management Sciences for Health, 2010 Management Sciences for Health, World Health Organization: International Drug Price Indicator Guide. 2010, Cambridge MA, USA: Management Sciences for Health, 2010
8.
go back to reference Morgan S, Daw J, Thomson P: International best practices for negotiating ‘reimbursement contracts’ with price rebates from pharmaceutical companies. Health Affairs. 2013, 32 (4): 771-777. 10.1377/hlthaff.2012.1268PubMedCrossRef Morgan S, Daw J, Thomson P: International best practices for negotiating ‘reimbursement contracts’ with price rebates from pharmaceutical companies. Health Affairs. 2013, 32 (4): 771-777. 10.1377/hlthaff.2012.1268PubMedCrossRef
9.
go back to reference World Health Assembly: 54th World Health Assembly: WHO medicines strategy: 21 May 2001. 2001, Geneva; Switzerland: World Health Organization World Health Assembly: 54th World Health Assembly: WHO medicines strategy: 21 May 2001. 2001, Geneva; Switzerland: World Health Organization
10.
go back to reference Austin AD, Gravelle J: Does Price Transparency Improve Market Efficiency? Implications of Empirical Evidence in Other Markets for the Health Sector. CRS Report for Congress, RL34101, 24 July 2007. 2007, Washington, D.C.: U.S: Congressional Research Service Austin AD, Gravelle J: Does Price Transparency Improve Market Efficiency? Implications of Empirical Evidence in Other Markets for the Health Sector. CRS Report for Congress, RL34101, 24 July 2007. 2007, Washington, D.C.: U.S: Congressional Research Service
11.
go back to reference Stigler GJ: The economics of information. J Pol Econ. 1961, 69 (3): 213-225. 10.1086/258464.CrossRef Stigler GJ: The economics of information. J Pol Econ. 1961, 69 (3): 213-225. 10.1086/258464.CrossRef
12.
go back to reference Pauly MV, Burns LR: Price transparency for medical devices. Health Affairs. 2008, 27 (6): 1544-1553. 10.1377/hlthaff.27.6.1544PubMedCrossRef Pauly MV, Burns LR: Price transparency for medical devices. Health Affairs. 2008, 27 (6): 1544-1553. 10.1377/hlthaff.27.6.1544PubMedCrossRef
13.
go back to reference Hviid M, Møllgaard HP: Countervailing power and price transparency. Scand J Econ. 2006, 108 (3): 499-512. 10.1111/j.1467-9442.2006.00468.x.CrossRef Hviid M, Møllgaard HP: Countervailing power and price transparency. Scand J Econ. 2006, 108 (3): 499-512. 10.1111/j.1467-9442.2006.00468.x.CrossRef
14.
go back to reference Ridley DB: Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics. 2005, 23 (7): 651-658. 10.2165/00019053-200523070-00002PubMedCrossRef Ridley DB: Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics. 2005, 23 (7): 651-658. 10.2165/00019053-200523070-00002PubMedCrossRef
15.
go back to reference Outterson K: Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005, 5 (1): 193-292.PubMed Outterson K: Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005, 5 (1): 193-292.PubMed
16.
go back to reference Pauly MV: Commentary. Drug and vaccine pricing and innovation: what is the story?. Managerial Decis Econ. 2007, 28: 407-413. 10.1002/mde.1351.CrossRef Pauly MV: Commentary. Drug and vaccine pricing and innovation: what is the story?. Managerial Decis Econ. 2007, 28: 407-413. 10.1002/mde.1351.CrossRef
17.
go back to reference Møllgaard P, Overgaard PB: Transparency and Competition Policy. The Pros and Cons of Information Sharing. 2006, 101-129. Stockholm, Sweden: Swedish Competition Authority Møllgaard P, Overgaard PB: Transparency and Competition Policy. The Pros and Cons of Information Sharing. 2006, 101-129. Stockholm, Sweden: Swedish Competition Authority
18.
go back to reference van Dongen S: Websites Reporting Medicine Prices: A Comparative Analysis. 2010, Geneva, Switzerland: World Health Organization in assoc. with Department of Pharmaceutical Sciences, Utrecht University, the Netherlands van Dongen S: Websites Reporting Medicine Prices: A Comparative Analysis. 2010, Geneva, Switzerland: World Health Organization in assoc. with Department of Pharmaceutical Sciences, Utrecht University, the Netherlands
19.
go back to reference Danzon PM, Chao L: Cross-national price differences for pharmaceuticals: how large, and why?. J Health Econ. 2000, 19: 159-195. 10.1016/S0167-6296(99)00039-9PubMedCrossRef Danzon PM, Chao L: Cross-national price differences for pharmaceuticals: how large, and why?. J Health Econ. 2000, 19: 159-195. 10.1016/S0167-6296(99)00039-9PubMedCrossRef
24.
go back to reference World Health Organization, Western Pacific Region: Price information exchange for selected medicines in the western pacific region. http://www.piemeds.com (Accessed March 15, 2013) World Health Organization, Western Pacific Region: Price information exchange for selected medicines in the western pacific region. http://​www.​piemeds.​com (Accessed March 15, 2013)
28.
go back to reference World Health Organization: Global Status Report on Noncommunicable Diseases. 2010, Geneva, Switzerland World Health Organization: Global Status Report on Noncommunicable Diseases. 2010, Geneva, Switzerland
29.
go back to reference Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Org. 2009, 87: 520-528. 10.2471/BLT.08.058925PubMedPubMedCentralCrossRef Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Org. 2009, 87: 520-528. 10.2471/BLT.08.058925PubMedPubMedCentralCrossRef
Metadata
Title
Enhancing medicine price transparency through price information mechanisms
Authors
Michael Hinsch
Miloud Kaddar
Sarah Schmitt
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2014
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/1744-8603-10-34

Other articles of this Issue 1/2014

Globalization and Health 1/2014 Go to the issue